Trials / Unknown
UnknownNCT04626908
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- He Huang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
Detailed description
This is a single-arm, single-center, open clinical study to evaluate the safety and efficacy of GC022F injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GC022F CAR-T cells | Each subject receive GC022F CAR-T cells by intravenous infusion |
Timeline
- Start date
- 2020-11-20
- Primary completion
- 2022-06-30
- Completion
- 2023-06-30
- First posted
- 2020-11-13
- Last updated
- 2020-11-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04626908. Inclusion in this directory is not an endorsement.